Download PDF
Neuropediatrics 2013; 44(06): 309-313
DOI: 10.1055/s-0033-1359308
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Treatment of Pediatric Multiple Sclerosis

Barbara Kornek
1   Department of Neurology, Medical University of Vienna, Vienna, Austria
› Author Affiliations
Further Information

Publication History

20 August 2013

29 September 2013

Publication Date:
07 November 2013 (online)

    Permissions and Reprints

Abstract

Multiple sclerosis (MS) in children and adolescents has received increased attention during the past decade. Although not tested in randomized placebo-controlled trials, first-line disease-modifying therapies are widely used in patients with MS who are younger than 18 years. This review summarizes current treatment practices, possible future treatment options, and gives insight into special problems in the treatment of pediatric patients with MS.

Keywords

multiple sclerosis - pediatric - disease-modifying therapy
 

  • References

  • 1 Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. University of British Columbia MS Clinic Neurologists Early onset multiple sclerosis: a longitudinal study. Neurology 2002; 59 (7) 1006-1010
    CrossrefPubMedGoogle Scholar
  • 2 Simone IL, Carrara D, Tortorella C , et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002; 59 (12) 1922-1928
    CrossrefPubMedGoogle Scholar
  • 3 Renoux C, Vukusic S, Mikaeloff Y , et al; Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356 (25) 2603-2613
    CrossrefPubMedGoogle Scholar
  • 4 Venkateswaran S, Banwell B. Pediatric multiple sclerosis. Neurologist 2010; 16 (2) 92-105
    CrossrefPubMedGoogle Scholar
  • 5 Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007; 6 (10) 887-902
    CrossrefPubMedGoogle Scholar
  • 6 Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LM. Italian Society of Paediatric Neurology Study Group on Childhood Multiple Sclerosis. Multiple sclerosis in children under 10 years of age. Neurol Sci 2004; 25 (Suppl. 04) S326-S335
    CrossrefPubMedGoogle Scholar
  • 7 Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009; 66 (1) 54-59
    CrossrefPubMedGoogle Scholar
  • 8 Julian L, Serafin D, Charvet L , et al; Network of Pediatric MS Centers of Excellence. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol 2013; 28 (1) 102-107
    CrossrefPubMedGoogle Scholar
  • 9 Amato MP, Goretti B, Ghezzi A , et al; Multiple Sclerosis Study Group of the Italian Neurological Society. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology 2010; 75 (13) 1134-1140
    CrossrefPubMedGoogle Scholar
  • 10 Banwell B. Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother 2005; 5 (3) 391-401
    CrossrefPubMedGoogle Scholar
  • 11 Pohl D, Waubant E, Banwell B , et al; International Pediatric MS Study Group. Treatment of pediatric multiple sclerosis and variants. Neurology 2007; 68 (16) (Suppl. 02) S54-S65
    CrossrefPubMedGoogle Scholar
  • 12 Ghezzi A, Banwell B, Boyko A , et al. The management of multiple sclerosis in children: a European view. Mult Scler 2010; 16 (10) 1258-1267
    CrossrefPubMedGoogle Scholar
  • 13 Ghezzi A. Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord 2010; 3 (4) 217-228
    CrossrefPubMedGoogle Scholar
  • 14 Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M. Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol 2011; 7 (2) 109-122
    CrossrefPubMedGoogle Scholar
  • 15 Chitnis T, Tenembaum S, Banwell B , et al; International Pediatric Multiple Sclerosis Study Group. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012; 18 (1) 116-127
    CrossrefPubMedGoogle Scholar
  • 16 Johnston J, So TY. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. Drugs 2012; 72 (9) 1195-1211
    CrossrefPubMedGoogle Scholar
  • 17 Chitnis T. Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics 2013; 10 (1) 89-96
    CrossrefPubMedGoogle Scholar
  • 18 Goodin DS, Frohman EM, Garmany Jr GP , et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58 (2) 169-178
    CrossrefPubMedGoogle Scholar
  • 19 Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359 (9313) 1221-1231
    CrossrefPubMedGoogle Scholar
  • 20 Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997; 49 (5) 1404-1413
    CrossrefPubMedGoogle Scholar
  • 21 Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL ; Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol 2011; 26 (6) 675-682
    CrossrefPubMedGoogle Scholar
  • 22 Weinshenker BG, O'Brien PC, Petterson TM , et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46 (6) 878-886
    CrossrefPubMedGoogle Scholar
  • 23 Takahashi I, Sawaishi Y, Takeda O, Enoki M, Takada G. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol 1997; 17 (1) 83-87
    CrossrefPubMedGoogle Scholar
  • 24 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43 (4) 655-661
    CrossrefPubMedGoogle Scholar
  • 25 Jacobs LD, Cookfair DL, Rudick RA , et al; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39 (3) 285-294
    CrossrefPubMedGoogle Scholar
  • 26 Group PRISMS. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352 (9139) 1498-1504
    CrossrefPubMedGoogle Scholar
  • 27 Johnson KP, Brooks BR, Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45 (7) 1268-1276
    CrossrefPubMedGoogle Scholar
  • 28 Jacobs LD, Beck RW, Simon JH , et al; CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343 (13) 898-904
    CrossrefPubMedGoogle Scholar
  • 29 Comi G, Filippi M, Barkhof F , et al; Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357 (9268) 1576-1582
    CrossrefPubMedGoogle Scholar
  • 30 Kappos L, Freedman MS, Polman CH , et al; BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370 (9585) 389-397
    CrossrefPubMedGoogle Scholar
  • 31 Comi G, Martinelli V, Rodegher M , et al; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374 (9700) 1503-1511
    CrossrefPubMedGoogle Scholar
  • 32 Filippini G, Del Giovane C, Vacchi L , et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. (Review) Cochrane Database Syst Rev 2013; 6: CD008933
    PubMedGoogle Scholar
  • 33 Ebers GC, Reder AT, Traboulsee A , et al; Investigators of the 16-Year Long-Term Follow-Up Study. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther 2009; 31 (8) 1724-1736
    CrossrefPubMedGoogle Scholar
  • 34 Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 2010; 16 (5) 588-596
    CrossrefPubMedGoogle Scholar
  • 35 Kappos L, Traboulsee A, Constantinescu C , et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67 (6) 944-953
    CrossrefPubMedGoogle Scholar
  • 36 Ford C, Goodman AD, Johnson K , et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010; 16 (3) 342-350
    CrossrefPubMedGoogle Scholar
  • 37 Goodin DS, Ebers GC, Cutter G , et al. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open 2012; 2 (6) e001972
    CrossrefPubMedGoogle Scholar
  • 38 Mikaeloff Y, Moreau T, Debouverie M , et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001; 139 (3) 443-446
    CrossrefPubMedGoogle Scholar
  • 39 Waubant E, Hietpas J, Stewart T , et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics 2001; 32 (4) 211-213
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Pohl D, Rostasy K, Gärtner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 2005; 64 (5) 888-890
    CrossrefPubMedGoogle Scholar
  • 41 Ghezzi A, Amato MP, Capobianco M , et al; Immunomodulatory Treatment of Early onset MS Group. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 2005; 11 (4) 420-424
    CrossrefPubMedGoogle Scholar
  • 42 Ghezzi A, Amato MP, Capobianco M , et al; Immunomodulatory Treatment of Early-onset MS (ITEMS) Group. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci 2007; 28 (3) 127-132
    CrossrefPubMedGoogle Scholar
  • 43 Banwell B, Reder AT, Krupp L , et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006; 66 (4) 472-476
    CrossrefPubMedGoogle Scholar
  • 44 Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 2006; 67 (3) 511-513
    CrossrefPubMedGoogle Scholar
  • 45 Mikaeloff Y, Caridade G, Tardieu M, Suissa S ; KIDSEP study group of the French Neuropediatric Society. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol 2008; 12 (3) 205-209
    CrossrefPubMedGoogle Scholar
  • 46 Tenembaum SN, Banwell B, Pohl D , et al; REPLAY Study Group. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol 2013; 28 (7) 849-856
    CrossrefPubMedGoogle Scholar
  • 47 Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 2003; 34 (3) 120-126
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Krupp LB, Banwell B, Tenembaum S ; International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007; 68 (16) (Suppl. 02) S7-S12
    CrossrefPubMedGoogle Scholar
  • 49 Krupp LB, Tardieu M, Amato MP , et al; International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19 (10) 1261-1267
    CrossrefPubMedGoogle Scholar
  • 50 Polman CH, Reingold SC, Banwell B , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69 (2) 292-302
    CrossrefPubMedGoogle Scholar
  • 51 Yeh EA, Waubant E, Krupp LB , et al; National Network of Pediatric MS Centers of Excellence. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol 2011; 68 (4) 437-444
    CrossrefPubMedGoogle Scholar
  • 52 Polman CH, O'Connor PW, Havrdova E , et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9) 899-910
    CrossrefPubMedGoogle Scholar
  • 53 Rudick RA, Stuart WH, Calabresi PA , et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9) 911-923
    CrossrefPubMedGoogle Scholar
  • 54 Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab use in pediatric multiple sclerosis. Arch Neurol 2008; 65 (12) 1655-1658
    CrossrefPubMedGoogle Scholar
  • 55 Borriello G, Prosperini L, Luchetti A , et al. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol 2009; 13: 76-71
    PubMedGoogle Scholar
  • 56 Ghezzi A, Pozzilli C, Grimaldi LM , et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 2010; 75 (10) 912-917
    CrossrefPubMedGoogle Scholar
  • 57 Ghezzi A, Pozzilli C, Grimaldi LME , et al; Italian MS Study Group. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler 2013; 19 (8) 1106-1112
    CrossrefPubMedGoogle Scholar
  • 58 Kornek B, Aboul-Enein F, Rostasy K , et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol 2013; 70 (4) 469-475
    CrossrefPubMedGoogle Scholar
  • 59 Bloomgren G, Richman S, Hotermans C , et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366 (20) 1870-1880
    CrossrefPubMedGoogle Scholar
  • 60 Kappos L, Bates D, Edan G , et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10 (8) 745-758
    CrossrefPubMedGoogle Scholar
  • 61 Sørensen PS, Bertolotto A, Edan G , et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18 (2) 143-152
    CrossrefPubMedGoogle Scholar
  • 62 Bozic C, Richman S, Plavina T. Prevalence of anti-JCV antibodies in MS patients receiving or considering treatment with natalizumab: baseline results of STRATIFY-1. Neurology 2011; 76 (Suppl. 04) A598
    PubMedGoogle Scholar
  • 63 Trampe AK, Hemmelmann C, Stroet A , et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012; 78 (22) 1736-1742
    CrossrefPubMedGoogle Scholar
  • 64 Kappos L, Radue EW, O'Connor P , et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362 (5) 387-401
    CrossrefPubMedGoogle Scholar
  • 65 Cohen JA, Barkhof F, Comi G , et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362 (5) 402-415
    CrossrefPubMedGoogle Scholar
  • 66 Oh J, O'Connor PW. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2013; 27 (8) 591-609
    CrossrefPubMedGoogle Scholar
  • 67 FDA. Gilenya (fingolimod): drug safety communication-safety review of a reported death after the first dose. 2011 , updated 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfor HumanMedicalProducts/ucm284355.htm
    PubMedGoogle Scholar
  • 68 Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009; 72 (24) 2076-2082
    CrossrefPubMedGoogle Scholar
  • 69 Hartung HP, Gonsette R, König N , et al; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360 (9350) 2018-2025
    CrossrefPubMedGoogle Scholar
  • 70 Kornek B, Bernert G, Rostasy K , et al. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics 2011; 42 (1) 7-12
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Fox RJ, Miller DH, Phillips JT , et al; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367 (12) 1087-1097
    CrossrefPubMedGoogle Scholar
  • 72 Gold R, Kappos L, Arnold DL , et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367 (12) 1098-1107
    CrossrefPubMedGoogle Scholar
  • 73 Ermis U, Wiesmann M, Nolte K , et al. Fumaric acid-associated progressive multifocal leukencephalopathy (PML), treatment and survival in a patient with psoriasis. (published online: September 30, 2011). Kongress der Deutschen Gesellschaft für Neurologie. 2011
    Google Scholar
  • 74 van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368 (17) 1658-1659
    CrossrefPubMedGoogle Scholar
  • 75 O'Connor P, Wolinsky JS, Confavreux C , et al; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365 (14) 1293-1303
    CrossrefPubMedGoogle Scholar
  • 76 Kappos L , ed. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER: a phase III, placebo-controlled study (Presentation 153). ECTRIMS, Lyon, France 2012
    Google Scholar
  • 77 Comi G, Jeffery D, Kappos L , et al; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366 (11) 1000-1009
    CrossrefPubMedGoogle Scholar
  • 78 Comi G, Vollmer T, Sorensen S , et al. Pooled analyses from the ALLEGRO and BRAVO trials on the safety and tolerability of laquinimod as a multiple sclerosis treatment (P04.132). American Academy of Neurology, New Orleans, USA; 2012
    Google Scholar
  • 79 Hauser SL, Waubant E, Arnold DL , et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358 (7) 676-688
    CrossrefPubMedGoogle Scholar
  • 80 Carson KR, Evens AM, Richey EA , et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113 (20) 4834-4840
    CrossrefPubMedGoogle Scholar
  • 81 Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2009; 2: 6609
    CrossrefPubMedGoogle Scholar
  • 82 Cohen JA, Coles AJ, Arnold DL , et al; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380 (9856) 1819-1828
    CrossrefPubMedGoogle Scholar
  • 83 Coles AJ, Twyman CL, Arnold DL , et al; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380 (9856) 1829-1839
    CrossrefPubMedGoogle Scholar
  • 84 Wynn D, Kaufman M, Montalban X , et al; CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9 (4) 381-390
    CrossrefPubMedGoogle Scholar
  • 85 Gold R, Giovannoni G, Selmaj K , et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381 (9884) 2167-2175
    CrossrefPubMedGoogle Scholar
  • 86 Gorman MP, Tillema JM, Ciliax AM, Guttmann CR, Chitnis T. Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol 2012; 69 (1) 78-81
    CrossrefPubMedGoogle Scholar
  • 87 Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013; 19 (1, Suppl A ): S24-S40
    PubMedGoogle Scholar